Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 09, 2024 08:45 ET | Source: Outlook Therapeutics, Inc.

Outlook Therapeutics® to Report Financial Results for Second Quarter Fiscal Year 2024 on May 16, 2024 and Host Inaugural Quarterly Conference Call and Webcast

ISELIN, N.J., May 09, 2024 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company working to achieve the first approval for an ophthalmic formulation of...
May 02, 2024 09:05 ET | Source: Outlook Therapeutics, Inc.

Outlook Therapeutics® to Present at the Retina World Congress 2024

ISELIN, N.J., May 02, 2024 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company working to achieve the first approval for an ophthalmic formulation of...
April 29, 2024 09:00 ET | Source: Outlook Therapeutics, Inc.

Outlook Therapeutics® to Present at the Ophthalmology Innovation Summit (OIS) Retina Innovation Showcase

ISELIN, N.J., April 29, 2024 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company working to achieve the first approval for an ophthalmic formulation of...
April 15, 2024 16:15 ET | Source: Outlook Therapeutics, Inc.

Outlook Therapeutics® Announces Closing of Private Placement of $5.0 Million

ISELIN, N.J., April 15, 2024 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company working to achieve the first approval for an ophthalmic formulation of...
March 22, 2024 07:35 ET | Source: Outlook Therapeutics, Inc.

Outlook Therapeutics® Receives European Union Positive CHMP Opinion for ONS-5010 as a Treatment for Wet AMD

Positive opinion serves as a basis for final decision for potential authorization from the European Commission (EC), expected within 67 days ISELIN, N.J., March 22, 2024 (GLOBE NEWSWIRE) -- Outlook...
March 18, 2024 17:10 ET | Source: Outlook Therapeutics, Inc.

Outlook Therapeutics® Announces Closing of Private Placement of up to $159 Million

ISELIN, N.J., March 18, 2024 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company working to achieve the first approval for an ophthalmic formulation of...
March 12, 2024 08:05 ET | Source: Outlook Therapeutics, Inc.

Outlook Therapeutics® Announces Effective Date for 1-for-20 Reverse Stock Split

ISELIN, N.J., March 12, 2024 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK) (the “Company”), a biopharmaceutical company working to achieve FDA approval for the first ophthalmic...
February 14, 2024 08:05 ET | Source: Outlook Therapeutics, Inc.

Outlook Therapeutics® Reports Financial Results for First Quarter Fiscal Year 2024 and Provides Corporate Update

NORSE EIGHT underway with first subject dosed and additional clinical sites beginning enrollment Continue to expect planned resubmission of the ONS-5010 Biologics License Application (BLA) by the end...
January 31, 2024 08:05 ET | Source: Outlook Therapeutics, Inc.

Outlook Therapeutics® Doses First Subject in NORSE EIGHT

NORSE EIGHT clinical trial is being conducted under Special Protocol Assessment (SPA) from FDA to support expected resubmission of the ONS-5010 Biologics License Application (BLA) by the end of...
January 23, 2024 08:00 ET | Source: Outlook Therapeutics, Inc.

Outlook Therapeutics® Receives FDA Agreement Under Special Protocol Assessment (SPA) for 90 Day Non-Inferiority Study, NORSE EIGHT, and Announces Private Placement of Up to $172 Million to Advance ONS-5010

Obtained clarity from U.S. Food and Drug Administration (FDA) on next steps to advance ONS-5010NORSE EIGHT expected to commence in the first quarter of CY2024, enabling potential resubmission of the...